15 results on '"Hamilou, Z."'
Search Results
2. 1382P FDG-positive/PSMA-negative PET lesion prevalence in metastatic castration-resistant prostate cancer and its correlation with lines of systemic therapy: Results from the prospective 3TMPO imaging study
- Author
-
Pouliot, F., Saad, F., Richard, P., Rousseau, E., Probst, S., Levesque, E., Castonguay, V., Marcoux, N., M. Lodde, Juneau, D., Hamilou, Z., Lattouf, J-B., Buteau, F-A., Pavic, M., Castilloux, J-F., Neveu, B., Bouvet, G., Tetu, A., Guérin, B., and Beauregard, J-M.
- Published
- 2022
- Full Text
- View/download PDF
3. Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma.
- Author
-
Hes C, Desilets A, Tonneau M, El Ouarzadi O, De Figueiredo Sousa M, Bahig H, Filion É, Nguyen-Tan PF, Christopoulos A, Benlaïfaoui M, Derosa L, Alves Costa Silva C, Ponce M, Malo J, Belkad W, Charpentier D, Aubin F, Hamilou Z, Jamal R, Messaoudene M, Soulières D, and Routy B
- Subjects
- Male, Humans, Female, Squamous Cell Carcinoma of Head and Neck complications, Prospective Studies, Chemoradiotherapy adverse effects, Head and Neck Neoplasms complications, Mucositis etiology, Gastrointestinal Microbiome
- Abstract
Objectives: Chemoradiation (CRT) in patients with locally advanced head and neck squamous cell cancer (HNSCC) is associated with significant toxicities, including mucositis. The gut microbiome represents an emerging hallmark of cancer and a potentially important biomarker for CRT-related adverse events. This prospective study investigated the association between the gut microbiome composition and CRT-related toxicities in patients with HNSCC, including mucositis., Materials and Methods: Stool samples from patients diagnosed with locally advanced HNSCC were prospectively collected prior to CRT initiation and analyzed using shotgun metagenomic sequencing to evaluate gut microbiome composition at baseline. Concurrently, clinicopathologic data, survival outcomes and the incidence and grading of CRT-emergent adverse events were documented in all patients., Results: A total of 52 patients were included, of whom 47 had baseline stool samples available for metagenomic analysis. Median age was 62, 83 % patients were men and 54 % had stage III-IV disease. All patients developed CRT-induced mucositis, including 42 % with severe events (i.e. CTCAE v5.0 grade ≥ 3) and 25 % who required enteral feeding. With a median follow-up of 26.5 months, patients with severe mucositis had shorter overall survival (HR = 3.3, 95 %CI 1.0-10.6; p = 0.02) and numerically shorter progression-free survival (HR = 2.8, 95 %CI, 0.8-9.6; p = 0.09). The gut microbiome beta-diversity of patients with severe mucositis differed from patients with grades 1-2 mucositis (p = 0.04), with enrichment in Mediterraneibacter (Ruminococcus gnavus) and Clostridiaceae family members, including Hungatella hathewayi. Grade 1-2 mucositis was associated with enrichment in Eubacterium rectale, Alistipes putredinis and Ruminococcaceae family members. Similar bacterial profiles were observed in patients who required enteral feeding., Conclusion: Patients who developed severe mucositis had decreased survival and enrichment in specific bacteria associated with mucosal inflammation. Interestingly, these same bacteria have been linked to immune checkpoint inhibitor resistance., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
4. Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada.
- Author
-
Gambaro K, Groleau M, McNamara S, Awan A, Salem M, Abdelsalam M, St-Hilaire E, Vincent F, Carrier J, MacKay H, Provencher L, Boudreau D, Hamilou Z, Saad F, Ferrario C, Batist G, and Marques M
- Subjects
- Humans, Female, Lapatinib therapeutic use, Retrospective Studies, Receptor, ErbB-2 analysis, Receptor, ErbB-2 therapeutic use, Canada, Ado-Trastuzumab Emtansine therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy
- Abstract
There is an increasing demand for real-world data pertaining to the usage of cancer treatments, especially in settings where no standard treatment is specifically recommended. This study presents the first real-world analysis of third-line treatment patterns in HER2-positive metastatic breast cancer (mBC) patients in Canada. The purpose was to assess evolution of clinical practice and identify unmet needs in post-second-line therapy. Retrospective data from medical records of 66 patients who received third-line treatment before 31st October 2018, and data from 56 patients who received third-line treatment after this date, extracted from the Personalize My Treatment (PMT) cancer patient registry, were analyzed. In the first cohort, the study revealed heterogeneity in the third-line setting, with trastuzumab, lapatinib, and T-DM1 being the main treatment options. Even though data were collected before the wide availability of tucatinib, neratinib and trastuzumab deruxtecan in Canada, the PMT cohort revealed the emergence of new therapeutic combinations and a shift from lapatinib usage to T-DM1 choice was observed. These findings underscore the evolving nature of third-line treatment strategies in Canada, a facet that is intrinsically tied to the availability of new drugs. The absence of a consensus on post-second-line treatment highlights the pressing need for more efficient therapeutic alternatives beyond the currently available options. This study not only offers valuable insights into the present landscape of third-line treatment in Canada but validates the significance and effectiveness of the PMT registry as a tool for generating pan-Canadian real-world evidence in oncology and its capacity to provide information on evolution of therapeutic practices., Competing Interests: Author MG was employed by company Knight Therapeutics Inc. This study received funding from Knight Therapeutics Inc. Knight Therapeutics had the following involvement with the study: CR cohort patient selection design and review of the manuscript., (Copyright © 2023 Gambaro, Groleau, McNamara, Awan, Salem, Abdelsalam, St-Hilaire, Vincent, Carrier, MacKay, Provencher, Boudreau, Hamilou, Saad, Ferrario, Batist and Marques.)
- Published
- 2023
- Full Text
- View/download PDF
5. A single-center, multidisciplinary experience with radium-223 dichloride in men with metastatic castrate-resistant prostate cancer.
- Author
-
Charrois-Durand C, Saad F, Barkati M, Lattouf JB, Perrotte P, Karakiewicz PI, Soulières D, Blais N, Hamilou Z, Juneau D, Plouznikoff N, Taussky D, and Delouya G
- Abstract
Introduction: We aimed to investigate several clinical and biochemical parameters, including palliative external beam radiation therapy (EBRT) to predict survival in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with radium-223 (
223 Ra)., Methods: We tested known and possible prognostic parameters, including palliative EBRT, both prior and concurrent to223 Ra. Logrank test (Kaplan-Meier method) and Cox regression analysis were used to predict overall survival (OS)., Results: A total of 133 patients were treated with223 Ra; median age was 72 years. Median OS was 9.0 (95% confidence interval [CI] 7.4-10.6) months. By univariate analysis (log-rank test), baseline Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 (p=0.001), ≥5 cycles of223 Ra (p<0.001), baseline hemoglobin (Hb) ≥120 g/L (p <0.001), baseline total alkaline phosphatase (tALP) <110 U/L (p=0.001), and any prostate-specific antigen (PSA) decline at week 12 (p=0.013) were associated with increased OS. EBRT prior and/or concurrent to223 Ra showed a trend (p=0.051) towards inferior OS by univariate analysis only. By multivariate analysis, significant factors were PS 0-1 (hazard ratio [HR] 1.94, 95% CI 1.3-2.9, p=0.001), Hb ≥120 g/L (HR 0.5, 95% CI 0.3-0.9, p=0.011), and absence of docetaxel use prior to223 Ra (HR 1.86, 95% CI 1.08-3.22, p=0.026). With baseline Hb, tALP, and ECOG PS, we were able to divide patients into three groups with different median OS (months): 23.0 (95% CI 12.8-33.2), 8.0 (95% CI 6.7-9.3), and 5.0 (95% CI 3.1-6.9) for low-, intermediate-, and high-risk, respectively (p<0.001)., Conclusions: We found that223 Ra therapy can result in an OS of close to two years in carefully selected patients. Earlier administration of223 Ra therapy to fitter patients with mCRPC should be tested.- Published
- 2022
- Full Text
- View/download PDF
6. Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context.
- Author
-
Kolinsky MP, Niederhoffer KY, Kwan EM, Hotte SJ, Hamilou Z, Yip SM, Chi KN, Wyatt AW, and Saad F
- Published
- 2022
- Full Text
- View/download PDF
7. Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?
- Author
-
Patrikidou A, Zilli T, Baciarello G, Terisse S, Hamilou Z, and Fizazi K
- Abstract
Biochemical recurrence is an evolving space in prostate cancer, with increasing multidisciplinary involvement. Androgen deprivation therapy has shown proof of its value in complementing salvage radiotherapy in high-risk biochemical relapsing patients; ongoing trials aim to further refine this treatment combination. As systemic treatments, and notably next-generation androgen receptor targeted agents, have moved towards early hormone-sensitive and non-metastatic stages, the prostate specific antigen (PSA)-relapse disease stage will be undoubtedly challenged by future evidence from such ongoing clinical trials. With the use of modern imaging and newer molecular technologies, including integration of tumoral genomic profiling and liquid biopsies in risk stratification, a path towards a precision oncology-focused approach will become a reality to guide in the future decisions for patients with a diagnosis of biochemical recurrence., Competing Interests: Conflict of interest statement: KK: Participation to advisory boards for: Amgen, Astellas, Astrazeneca, AAA, Bayer, Clovis, Curevac, ESSA, Genentech, Janssen, MSD, Orion, Sanofi. Honoraria are provided to Gustave Roussy, my institution. TZ: Honoraria (to institution)/travel grants — Janssen, Amgen, Ferring, Debiopharm, Bayer, Astellas. Research Grants — Varian Medical Systems GB: Advisory boards and symposia: Amgen, Janssen Oncology, Sanofi, Astellas-Pharma, Roche, Bayer, Genesta. Travel accomodations, expenses: Amgen, Astellas-Pharma, Astra Zeneca, Ipsen, Janssen Oncology, Sanofi AP: advisory boards: Basilea, Congress participation: Amgen, (© The Author(s), 2021.)
- Published
- 2021
- Full Text
- View/download PDF
8. A drug safety evaluation of enzalutamide to treat advanced prostate cancer.
- Author
-
Saad F, Hamilou Z, and Lattouf JB
- Subjects
- Androgen Receptor Antagonists administration & dosage, Androgen Receptor Antagonists adverse effects, Antineoplastic Agents adverse effects, Benzamides adverse effects, Humans, Male, Nitriles adverse effects, Phenylthiohydantoin adverse effects, Prostatic Neoplasms pathology, Quality of Life, Antineoplastic Agents administration & dosage, Benzamides administration & dosage, Nitriles administration & dosage, Phenylthiohydantoin administration & dosage, Prostatic Neoplasms drug therapy
- Abstract
Introduction: Prostate cancer (PC) is the most common cancer in North American men. Advanced PC is incurable. The androgen receptor antagonist enzalutamide is used to manage advanced PC, often over a period of months or years; it is therefore important to evaluate the safety profile of enzalutamide., Areas Covered: This literature review presents safety data from pivotal trials and real-world data studies of enzalutamide in patients with advanced PC, including metastatic hormone-sensitive prostate cancer (mHSPC), nonmetastatic castration-resistant prostate cancer (nmCRPC), and metastatic castration-resistant prostate cancer (mCRPC). A large body of evidence supports the maintenance or improvement in the health-related quality of life (HRQoL) afforded by enzalutamide treatment in patients with mHSPC, nmCRPC, or chemotherapy-naïve mCRPC, as well as improvement in the HRQoL in patients with later-stage symptomatic mCRPC. Efficacy data from clinical trials are also briefly discussed., Expert Opinion: We aim to provide clinicians with a better understanding of how to properly interpret enzalutamide clinical trial safety data. This knowledge may help clinicians guide their patients with PC to achieve optimal clinical benefit from enzalutamide therapy, and to properly manage their patients to mitigate any potential risk.
- Published
- 2021
- Full Text
- View/download PDF
9. The evolving options in metastatic castration-sensitive prostate cancer.
- Author
-
Hamilou Z
- Subjects
- Androgen Antagonists administration & dosage, Androgen Antagonists adverse effects, Androstenes therapeutic use, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Benzamides therapeutic use, Docetaxel therapeutic use, Drug Therapy, Combination, Humans, Male, Neoplasm Metastasis, Nitriles therapeutic use, Phenylthiohydantoin therapeutic use, Prostatic Neoplasms pathology, Randomized Controlled Trials as Topic, Androgen Antagonists therapeutic use, Antineoplastic Agents therapeutic use, Prostatic Neoplasms drug therapy
- Abstract
Purpose of Review: Leading trials CHAARTED, STAMPEDE, GETUG-AFU15 and LATITUDE established docetaxel and abiraterone acetate addition to androgen deprivation therapy (ADT) as a treatment guideline for patients with metastatic castration-sensitive prostate cancer., Recent Findings: Two recent combinations, enzalutamide with ADT and apalutamide with ADT were tested in metastatic castration-sensitive prostate cancer in three randomized controlled trials. Both combinations provided survival gain, expanding our options of treatment. Moreover, additional evidence behind radiotherapy for the primary tumor in metastatic prostate cancer is emerging., Summary: In this updated article, we review the data of these trials and highlight the distinctions between these therapies, in order to better personalize the care for patients with metastatic prostate cancer.
- Published
- 2020
- Full Text
- View/download PDF
10. Management of urachal cancer: A consensus statement by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada.
- Author
-
Hamilou Z, North S, Canil C, Wood L, Hotte S, Sridhar SS, Soulières D, Latour M, Taussky D, Kassouf W, and Blais N
- Published
- 2020
- Full Text
- View/download PDF
11. Treatment of hormone-naïve metastatic prostate cancer.
- Author
-
Hamilou Z, Saad F, and Fizazi K
- Subjects
- Androgen Antagonists administration & dosage, Androgen Antagonists adverse effects, Androstenes administration & dosage, Androstenes adverse effects, Clinical Trials, Phase III as Topic, Docetaxel administration & dosage, Docetaxel adverse effects, Drug Therapy, Combination, Humans, Male, Neoplasm Metastasis, Prospective Studies, Prostatic Neoplasms mortality, Prostatic Neoplasms pathology, Prostatic Neoplasms, Castration-Resistant drug therapy, Prostatic Neoplasms, Castration-Resistant pathology, Randomized Controlled Trials as Topic, Androgen Antagonists therapeutic use, Androstenes therapeutic use, Docetaxel therapeutic use, Prostatic Neoplasms drug therapy
- Abstract
Purpose of Review: Until 2015, androgen deprivation therapy (ADT) alone was the standard-of-care for metastatic hormone-naïve prostate cancer (mHNPC). In the last decade, important landmark therapeutic advances occurred in the management of these patients permitting improvement of their survival., Recent Findings: At least two prospective randomized trials proved upfront docetaxel (DOC) + ADT benefit consequently providing strong evidence for guidelines modifications. Second, similar benefit results were demonstrated when using upfront abiraterone acetate + ADT in mHNPC., Summary: Both DOC-based chemotherapy and abiraterone acetate provide survival improvement when added to ADT in mHNPC. In the current article, we review the evidence behind this progress and discuss ongoing clinical controversies.
- Published
- 2018
- Full Text
- View/download PDF
12. Durvalumab in urothelial cancers.
- Author
-
Lavaud P, Hamilou Z, Loriot Y, and Massard C
- Subjects
- Antibodies, Monoclonal adverse effects, Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Agents, Immunological adverse effects, Biomarkers, Tumor metabolism, Carcinoma, Transitional Cell pathology, Humans, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Urinary Bladder Neoplasms pathology, Antibodies, Monoclonal administration & dosage, Carcinoma, Transitional Cell drug therapy, Urinary Bladder Neoplasms drug therapy
- Abstract
Introduction: Urothelial bladder cancer is one of the most predominant malignancies worldwide with a poor prognosis when presented at an advanced or metastatic stage. Improving the therapeutic landscape in this setting has been an unmet medical need. Palliative cisplatin-based chemotherapy is currently the standard of care in first line therapies, but many patients are ineligible and few alternative therapies exist. Moreover second-line chemotherapy has minimal activity. Recently, immune-checkpoint inhibitors have shifted the therapeutic armamentarium of bladder cancer and it is now necessary to redesign the therapeutic paradigm. Areas covered: In this article, we focus on the development of durvalumab and provide an overview of the safety, activity, efficacy and future perspectives of this drug in urothelial carcinoma. Expert commentary: Durvalumab is a well-tolerated drug and demonstrated major and durable response in advanced bladder cancer. Combinations with durvalumab will probably emerge as promising therapeutic strategies for the treatment of urothelial carcinoma. Further research efforts are needed to identify predictive biomarkers of response to immune-oncology agents.
- Published
- 2018
- Full Text
- View/download PDF
13. Atezolizumab in urothelial bladder carcinoma.
- Author
-
Hamilou Z, Lavaud P, and Loriot Y
- Subjects
- Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal pharmacokinetics, Antibodies, Monoclonal, Humanized, B7-H1 Antigen antagonists & inhibitors, B7-H1 Antigen immunology, CTLA-4 Antigen antagonists & inhibitors, CTLA-4 Antigen immunology, Humans, Neoplasm Metastasis, Urinary Bladder Neoplasms pathology, Urothelium drug effects, Urothelium pathology, Antibodies, Monoclonal therapeutic use, Cisplatin adverse effects, Immunotherapy, Urinary Bladder Neoplasms drug therapy
- Abstract
Metastatic bladder cancer is an aggressive malignancy with a poor prognosis when presenting with advanced stage. Cisplatin-based therapy has been the mainstay of first-line treatment but therapy in second-line setting has been an unmet medical need for decades. Moreover, many patients are unable to receive cisplatin-based therapy. Recently, immune-checkpoint inhibitors transformed the management and prognosis of many malignancies and will certainly redefine the standard of care for bladder cancer. Atezolizumab, an anti-PD-L1 antibody, was the first immune-checkpoint inhibitor to be approved by the US FDA in May 2016 for patients with urothelial carcinoma. In this review, we discuss the evidence behind this promising drug.
- Published
- 2018
- Full Text
- View/download PDF
14. Treatment of Castration-naive Metastatic Prostate Cancer.
- Author
-
Hamilou Z, Baciarello G, and Fizazi K
- Subjects
- Abiraterone Acetate administration & dosage, Androgen Antagonists administration & dosage, Antineoplastic Agents, Hormonal administration & dosage, Disease-Free Survival, Docetaxel administration & dosage, Drug Administration Schedule, Humans, Male, Neoplasm Metastasis, Prednisone administration & dosage, Prostatic Neoplasms, Castration-Resistant mortality, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Prostatic Neoplasms, Castration-Resistant drug therapy
- Abstract
Both docetaxel+androgen deprivation therapy (ADT) and abiraterone acetate 1000mg/d+prednisone/prednisolone 5mg/d+ADT improved survival in patients with metastatic castration-naive prostate cancer. Their use should be offered and guided by patient's own characteristics., (Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
15. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.
- Author
-
Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z, Mollica L, Li J, Viale A, Heguy A, Hassimi M, Socci N, Bhatt PK, Gonen M, Mason CE, Melnick A, Godley LA, Brennan CW, Abdel-Wahab O, and Levine RL
- Subjects
- 5-Methylcytosine metabolism, Dioxygenases, Exome, Female, Hematopoiesis, Humans, X Chromosome Inactivation, Aging genetics, DNA Methylation genetics, DNA-Binding Proteins genetics, DNA-Binding Proteins metabolism, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins metabolism
- Abstract
Aging is characterized by clonal expansion of myeloid-biased hematopoietic stem cells and by increased risk of myeloid malignancies. Exome sequencing of three elderly females with clonal hematopoiesis, demonstrated by X-inactivation analysis, identified somatic TET2 mutations. Recurrence testing identified TET2 mutations in 10 out of 182 individuals with X-inactivation skewing. TET2 mutations were specific to individuals with clonal hematopoiesis without hematological malignancies and were associated with alterations in DNA methylation.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.